Thrombin-activated inhibitor of fibrinolysis and efficacy and safety of long-term warfarin treatment in patients with venous thromboembolic complications


如何引用文章

全文:

详细

Aim. To study effects of thrombin-activated fibrinolysis inhibitor (TAFI) on efficacy and safety of long-term anti-coagulant treatment in patients with venous thromboembolic complications (VTEC). Material and methods. A total of 111 patients with a history of an episode of deep vein thrombosis (DVT) and/or pulmonary artery thromboembolism (PATE) entered the study. All the patients received unfractionated or low-molecular heparin for at least 5 days than switch on warfarin (target values of INR 2,0-3,0). Baseline blood levels of TAFI were measured. The patients were followed up for 18 months. Recurrent (DVT/TAFI and hemorrhagic complications (HC) were end points. Also, frequency of complete lysis of deep vein thrombi was assessed after 12 months of treatment.
Results. A TAFI level varied from 50 to 217% (median 106%, interquartile rage 90-133%). TAFI concentration positively correlated with fibrinogen and thromb size. The patients were divided into two groups depending on TAFI content: group 1 patients had low TAFI (under 25th percentile; < 90%); patients of group 2 had high TAFI (above 25th percentile; > 90%). Group 1 patients were characterized by less stable anticoagulation. This association did not depend on genetic characteristics which determine sensitivity to warfarin (CYP2C9 and VKORC1). Low TAFI was associated with reduced risk of DVT for 18 months and higher probability of complete lysis of the thrombi after 12 months of anticoagulant therapy compared to VTEC patients with high TAFI. No differences were found by TAFI level in patients with HC and without HC, but in HC patients low TAFI was associated with spontaneous hemorrhages and bleeding in therapeutic INR values.
Conclusion. The results of this pilot study evidence that a TAFI level can be one of the factors influencing efficacy and safety of long-term anticoagulant therapy in patients with VTEC on warfarin treatment.

作者简介

Natal'ya Vorob'eva

Email: natalyavorobjeva@mail.ru

Elizaveta Panchenko

Email: lizapanchenko@mail.ru

Anatoliy Dobrovol'skiy

Email: abdobrovolsky@inbox.ru

Elena Titaeva

Email: evlti@mail.ru

O Ermolina

T Balakhonova

Zukhra Khasanova

Email: khasanova@mail.ru

Anton Postnov

Email: anton-5@mail.ru

Aleksandr Kirienko

Email: phlebo-union@mtu-net.ru

N Vorobyeva

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

E Panchenko

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

A Dobrovolsky

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

E Titaeva

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

O Ermolina

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

T Balakhonova

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

Z Khasanova

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

A Postnov

Russian Research Cardiology Center, Moscow

Russian Research Cardiology Center, Moscow

A Kirienko

N. I. Pirogov Russian State Moscow University, Moscow

N. I. Pirogov Russian State Moscow University, Moscow

参考

  1. Silverstein M. D., Heit J. A., Mohr D. N. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 1998; 158: 585-593.
  2. Kyrle P. A., Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163-1174.
  3. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb. Haemost. 2000; 83: 657-660.
  4. Crawley J. Т. В., Zanardelli S., Chion С. К. N. K., Lane D. A. The central role of thrombin in hemostasis. J. Thromb. Haemost. 2007; 5 (Suppl. 1): 95-101.
  5. van Hinsbergh V. W., Bertina R. M., van Wijngaarden A. et al. Activated protein С decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451.
  6. Taylor F. B. Jr., Lockhart M. S. A new function for activated protein C: activated protein С prevents inhibition of plasminogen activators by releasate from mononuclear leukocytes-platelet suspensions stimulated by phorbol diester. Thromb Res. 1985; 37: 155-164.
  7. Bajzar L., Nesheim M. The effect of activated protein С on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation. J. Biol. Chem. 1993; 268: 8608-8616.
  8. de Fouw N. J., Haverkate F., Bertina R. M. et al. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein С in vitro. Blood 1986; 67: 1189-1192.
  9. de Fouw N. J., Haverkate F., Bertina R. M. Protein С and fibrinolysis: a link between coagulation and fibrinolysis. Adv. Exp. Med. Biol. 1990; 281: 235-243.
  10. Bajzar L., Manuel R., Nesheim M. E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 1995; 270: 14477-14484.
  11. Eaton D. L., Malloy В. Е., Tsai S. P. et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase В from human plasma. J. Biol. Chem. 1991; 266: 21833- 21838.
  12. Hendriks D., Wang W., van Sande M., Scharpe S. Human serum carboxypeptidase U: a new kininase? Agents and Actions Suppl. 1992; 38: 407-413.
  13. van Tilburg N. H., Rosendaal F. R., Bertina R. M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
  14. Folkeringa N., Coppens M., Veeger N. J. et al. Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. Thromb. Haemost. 2008; 100: 38-44.
  15. Lijfering W. M., Brouwer J. L., Veeger N. J. et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-5322.
  16. Kearon C., Kahn S. R., Agnelli G. et al. Antithrombotic therapy for venous throm-boembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (Suppl.): 454S-545S.
  17. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2008; 29: 2276-2315.
  18. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 1: 4-37.
  19. Fihn S. D., McDonell M., Martin D. et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann. Intern. Med. 1993; 118: 511-520.
  20. Bajzar L., Nesheim M. E., Tracy P. B. The profibrinolytic effect of activated protein С in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
  21. Nesheim M. Fibrinolysis and the plasma carboxypeptidase. Curr. Opin. Hematol. 1998; 5: 309-313.
  22. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 1996; 271: 16603-16608.
  23. Nesheim M., Wang W., Boffa M. et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb. Haemost. 1997; 78: 386-391.
  24. Eichinger S., Schönauer V., Weltermann A. et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-3776.
  25. Henry M., Aubert H., Morange P. E. et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-2058.
  26. Martini C. H., Brandts A., de Bruijne E. L. E. et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br. J. Haematol. 2006; 134: 92-94.
  27. Brouwers G. J., Vos H. L., Leebeek F. W. G. et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFl levels. Blood 2001; 98: 1992-1993.
  28. Franco R. F., Fagundes M. G., Meijers J. С et al. Identification of polymorphisms in the 5'-untranslated region of the tafi gene: relationship with plasma tafi levels and risk of venous thrombosis. Haematologica 2001; 86: 510-517.
  29. Zidane M., de Visser M. C., ten Wolde M. et al. Frequency of the TAFI - 438G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb. Haemost. 2003; 90: 439-445.
  30. Mosnier L. O., von dem Borne P. A., Meijers J. C., Bouma B. N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb. Haemost. 1998; 80: 829-835.
  31. Lisman Т., de Groot P. G., Meijers J. С. М., Rosendaal F. R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2011

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##